Show simple item record

dc.contributor.authorRíos-Tamayo, Rafael
dc.contributor.authorLecumberri, Ramón
dc.contributor.authorCibeira, María Teresa
dc.contributor.authorGonzález-Calle, Verónica
dc.contributor.authorAlonso, Rafael
dc.contributor.authorDomingo-González, Amalia
dc.contributor.authorLandete, Elena
dc.contributor.authorEncinas, Cristina
dc.contributor.authorIñigo, Belén
dc.contributor.authorBlanchard, María-Jesús
dc.contributor.authorAlejo, Elena
dc.contributor.authorKrsnik, Isabel
dc.contributor.authorGómez-Bueno, Manuel
dc.contributor.authorGarcia-Pavia, Pablo 
dc.contributor.authorSegovia-Cubero, Javier
dc.contributor.authorRosiñol, Laura
dc.contributor.authorLahuerta, Juan-José
dc.contributor.authorMartínez-López, Joaquín
dc.contributor.authorBladé, Joan
dc.date.accessioned2024-07-02T10:11:06Z
dc.date.available2024-07-02T10:11:06Z
dc.date.issued2024-04-26
dc.identifier.citationCancers (Basel). 2024 Apr 26;16(9):1689.es_ES
dc.identifier.issn2072-6694es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19903
dc.description.abstractSystemic AL amyloidosis is a challenging disease for which many patients are considered frail in daily clinical practice. However, no study has so far addressed frailty and its impact on the outcome of these patients. We built a simple score to predict mortality based on three frailty-associated variables: age, ECOG performance status (<2 vs. ≥2) and NT-proBNP (<8500 vs. ≥8500 ng/L). Four-hundred and sixteen consecutive newly diagnosed patients diagnosed at ten sites from the Spanish Myeloma Group were eligible for the study. The score was developed in a derivation cohort from a referral center, and it was externally validated in a multicenter cohort. Multivariate analysis showed that the three variables were independent predictors of survival. The score was able to discriminate four groups of patients in terms of overall survival and early mortality in both cohorts. Comorbidity was also analyzed with the Charlson comorbidity index, but it did not reach statistical significance in the model. A nomogram was created to easily estimate the mortality risk of each patient at each time point. This score is a simple, robust, and efficient approach to dynamically assess frailty-dependent mortality both at diagnosis and throughout follow-up. The optimal treatment for frail AL amyloidosis patients remains to be determined but we suggest that the estimation of frailty-associated risk could complement current staging systems, adding value in clinical decision-making in this complex scenario.es_ES
dc.description.sponsorshipThis research received no external funding.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleA Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID38730641es_ES
dc.format.volume16es_ES
dc.format.number9es_ES
dc.identifier.doi10.3390/cancers16091689es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversion10.3390/cancers16091689es_ES
dc.identifier.journalCancerses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Miocardiopatías Hereditariases_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional